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Abstract
Background: Satellite cells (SCs) are indispensable for muscle regeneration and repair; however, due to low
frequency in primary muscle and loss of engraftment potential after ex vivo expansion, their use in cell therapy is
currently unfeasible. To date, an alternative to this limitation has been the transplantation of SC-derived myogenic
progenitor cells (MPCs), although these do not hold the same attractive properties of stem cells, such as self-
renewal and long-term regenerative potential.
Methods: We develop a method to expand wild-type and dystrophic fresh isolated satellite cells using transient
expression of Pax3. This approach can be combined with genetic correction of dystrophic satellite cells and utilized
to promote muscle regeneration when transplanted into dystrophic mice.
Results: Here, we show that SCs from wild-type and dystrophic mice can be expanded in culture through transient
expression of Pax3, and these expanded activated SCs can regenerate the muscle. We test this approach in a gene
therapy model by correcting dystrophic SCs from a mouse lacking dystrophin using a Sleeping Beauty transposon
carrying the human μDYSTROPHIN gene. Transplantation of these expanded corrected cells into immune-deficient,
dystrophin-deficient mice generated large numbers of dystrophin-expressing myofibers and improved contractile
strength. Importantly, in vitro expanded SCs engrafted the SC compartment and could regenerate muscle after
secondary injury.
Conclusion: These results demonstrate that Pax3 is able to promote the ex vivo expansion of SCs while
maintaining their stem cell regenerative properties.
Keywords: Satellite cells, Muscular dystrophy, Gene correction, Sleeping Beauty, Dystrophin, Pax3, Regeneration
Background
Duchenne muscular dystrophy is a fatal neuromuscu-
lar disease affecting about 1 in 5000 boys [1], which
is caused by mutations in the gene coding for the
dystrophin protein [2]. Its absence results in continual
damage and regeneration, which becomes impaired
over time, leading to displacement of muscle fibers
with fat and connective tissue, resulting in diminished
muscle function [3]. Loss of regeneration is thought
to be due to exhaustion or impairment of satellite
cells. These are resident adult muscle stem cells lo-
cated underneath the basal lamina [4] that actively
contribute to skeletal muscle growth and regeneration
throughout life [5]. Under normal physiological condi-
tions, satellite cells are quiescent [6] and express
Pax7 [7]. In response to injury, satellite cells become
activated and proliferate as myogenic progenitor cells
(MPCs), migrate to the damaged area, and fuse to
form new multinucleated myofibers [8, 9]. This period
of extensive proliferation terminates when homeosta-
sis is achieved and injury is repaired [10]. During this
process, a small proportion of satellite cells re-enter
quiescence [11, 12] and reconstitute the satellite cell
pool. These characteristics make satellite cells an at-
tractive cell population to be utilized in cell-based
therapies to treat muscular dystrophies.
Numerous studies have investigated the regenerative
potential of satellite cells and their progeny derivatives
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[10, 13–20]. However, ex vivo expanded satellite cells
have diminished regenerative potential in vivo [21].
Tremblay and colleagues have conducted a phase I
clinical trial for MPC cultures using a high-density
injection approach in DMD patients, which has been
reported encouraging in the sense dystrophin expres-
sion could be detected [22–24]. Nevertheless, MPCs
are not the most desirable population to be trans-
planted since these cells are characterized by limited
survival and migration upon injection [25–28] and,
more importantly, are devoid of self-renewal, which
limits their long-term regeneration potential. Thus, an
essential requirement for muscle cell-based therapies
is the development of an approach that enables the
ex vivo expansion of satellite cells while maintaining
their “stemness” and regeneration potential.
Here, we show that this can be accomplished in
mouse satellite cells by transient expression of Pax3,
the master regulator of the embryonic myogenic pro-
gram, and that ex vivo expanded satellite cell progeny
have a high capacity for engraftment and regener-
ation. Most importantly, we demonstrate that this sys-
tem can be combined with genetic correction of cells
from dystrophic animals and utilized to promote
muscle regeneration and improve functional proper-
ties in vivo when transplanted back into dystrophic
mice.
Methods
Mice and satellite cell isolation
Animal maintenance and experimental use were per-
formed according to protocols approved by the Univer-
sity of Minnesota Institutional Animal Care and Use
Committee. The transgenic Pax7-ZsGreen reporter
mouse line was generated by injection of the purified
Pax7-BAC (RP23–218H13) containing a ZsGreen fluores-
cence protein into the first coding exon, as described [29].
Pax7-ZsGreen/mdx mice were generated by breeding mdx
mice (C57BL/10ScSn), purchased from Jackson Laborator-
ies (Bar Harbor, ME, http://www.jax.org), to WT-Pax7-
ZsGreen mice [29]. Female progeny containing both genes
were crossed to hemizygous mdx male mice. R26-M2rtTA/
M2rtTA mice [30] were also bred to Pax7-ZsGreen mice.
Resulting mice from this breeding were intercrossed, and
mice homozygous for at the R26-M2rtTA were identified.
NSG-mdx4Cv mice [31] were used as transplantation recip-
ients. Pax7-ZsGreen satellite cells were isolated from so-
leus (SOL), extensor digitorum longus (EDL), tibialis
anterior (TA), and gastrocnemius (GAS) muscles of 6–8-
week-old Pax7-ZsGreen/mdx or R26-M2rtTA/M2rtTA;-
Pax7-ZsGreen mice, as described previously [29]. Analysis
and cell sorting were performed on a Cytomation MoFlo cyt-
ometer (Dako, Carpinteria, CA, http://www.dako.com).
Generation of Pax3-induced cells
Freshly isolated satellite cells were immediately trans-
duced with the inducible Pax3-IRES-mCherry-expressing
lentivector [32] to generate the Pax3-induced satellite cells
and mdx-Pax3-induced satellite cells; control satellite cells
were transduced with mCherry lentiviral vector.
Sleeping Beauty system and generation of corrected
μDYS-Pax3-induced cells
We developed a bicistronic T2-inverted terminal repeat
transposon (Tn) vector (pKt2-GFP-Neo/μDYSTROPHIN)
carrying an 11.3-kb engineered transgene containing the
skeletal α-actin promoter (pHSA) (generously provided by
Jeffrey Chamberlain, Department of Neurology, University
of Washington School of Medicine) that drives μDYS and
a ubiquitin promoter (hEF1a-eIF4g) that drives a GFP-2A-
Neo reporter gene, which allows for the selection of
μDYS-corrected mdx-Pax3-induced cells. The whole
transgene is flanked by the terminal inverted repeats
(IR/DR), each of which contains two binding sites for
the transposase. For the transposase, we used pCMV-
SB100X (generously provided by Zoltan Ivics from Max
Delbruck Center for Molecular Medicine, Berlin), which
yields high levels of Tn integration. SB transposase-
mediated gene delivery was done using an Amaxa Nucleo-
fector (Lonza) according to the manufacturer’s protocol
(fibroblast Nucleofector kit solution, Nucleofector pro-
gram U-023). 5 × 105 mdx-Pax3-induced cells were
nucleofected with 1 μg of pCMV-SB100X and 4 μg of
Tn:pKt2-GFP-Neo/μH2-μDYS. Corrected μDYS-Pax3-in-
duced satellite cell (SC) Pax3 cells were purified based on
sorting for GFP+ cells. The μDYS was generated using the
full-length human dystrophin cDNA in the Gateway entry
vector pENTR223.1 (NM_004006) that was obtained from
the ORFeome Collaboration. The entry vector was N-
terminally FLAG-tagged via PCR using primers with over-
hangs encoding the tag. The μ -dystrophinΔR4–23/ΔCT
(μDYS) was built by deletion using previously described
methods [33]. Briefly, PCR primers were designed such
that they amplified the entire plasmid except the region
being deleted, namely spectrin-like repeats 4–23. These
linear PCR products were then circularized via the
addition of T4 polynucleotide kinase and T4 DNA ligase
(New England Biolabs) and sequence verified. A second
round of PCR and circularization was performed to delete
the C-terminus. All PCRs were performed using PfuUltra
II HS polymerase (Stratagene).
RNA extraction and real-time PCR analysis
RNA was isolated from cultured cells using TRIzol re-
agent (Life Technology). One microgram of total RNA
was reverse-transcribed using the ThermoScript™ Reverse
Transcriptase kit (Life Technology). In control uninduced
and Pax3-induced cells, real-time PCR was performed for
Filareto et al. Skeletal Muscle  (2015) 5:36 Page 2 of 11
muscle-specific genes with probe sets from Applied
Biosystems [34]. To confirm μDYS expression in corrected
Pax3-induced cells, specific primers were designed for the
μDYS gene (F: 5′-TTCTAAGTTTGGGAAGCAGCA-3′
and R: GGTCTGGCCTATGACTATGGA. Primers for
GAPDH were F: AGGCCGGTGCTGAGTATGTC and R:
TGCCCTGCTTCACCACCTTCT).
Muscle injury and transplantation studies
Four-month-old NSG-mdx4Cv mice were used as recipi-
ents for all transplantation studies described here.
Muscle injury was performed as described previously
[31]. Briefly, both hind limbs were subjected to
1200 cGy of irradiation at day 2; muscle injury was in-
duced 24 hours later (day 1) using 15 μl of cardiotoxin
(10 μM, SIGMA) in both right and left TA muscle; on
day 0, cells were injected into the left TA of each mouse
using a Hamilton syringe. For each set of transplant-
ation, cells were collected using cell dissociation buffer,
enzyme-free (GIBCO) (10 min at 37 °C), resuspended in
PBS, and then injected directly into the left TA muscle
(350,000 cells per 10 μl PBS). Control TA muscles were
injected with the same volume of PBS.
Immunofluorescence of cultured cells and tissue sections
TA muscles were embedded in Tissue-Tek OCT com-
pound and immediately frozen in liquid nitrogen-cooled
isopentane. Cut tissues (10–12 μm) were permeabilized
with 0.3 % Triton X-100 in PBS for 10 min, then blocked
for 1 h in 20 % goat serum, and incubated overnight
with specific primary antibody in antibody diluent (Dako).
Primary antibodies used were rabbit anti-dystrophin
polyclonal antibody (1:250, ab 15277; Abcam), mouse
anti-dystrophin polyclonal antibody specific for human
μDys (1:50, MAB1690; Chemicon, Millipore), mouse anti-
Pax7 (1:250; MAB 1675; R&D System), rabbit anti-laminin
(1:400; Sigma), anti-rabbit ZsGreen (1:100; Clontech), and
anti-embryonic MHC (1:20; F1.652; Developmental Stud-
ies Hybridoma Bank). For ZsGreen staining, tissues were
collected and immediately fixed in 4 % PFA for 1 h. Next
slides were incubated in a solution of 30 % sucrose in
0.01 M PBS for 2 h and left over night in a solution of
20 % sucrose in 0.01 M PBS. The next day, TA muscles
were embedded in OCT compound (Leica). A MOM kit
(Vector Laboratory) was used following the manufac-
turer’s instruction. After three PBS washes, sections were
incubated for 45 min with secondary antibody. For sec-
ondary staining, goat Alexa-555 anti-rabbit or mouse,
Alexa-488 anti-rabbit or mouse, Alexa-647 anti-rabbit,
and Alexa-488 anti-chicken (1:1000) were used (Molecular
Probes). Control tissues were processed simultaneously in
the same manner.
For in vitro cultures, cells were maintained on gelatin-
coated plates and processed as described above. Cells
were first fixed for 10 min at RT in 4 % PFA, washed
twice in PBS, and incubated for 10 min with 0.3 %
Triton X-100 in PBS. The following primary anti-
bodies were used: anti-Pax3 (1:100; R&D Systems)
and anti-MHC (1:50; MF20; Developmental Studies
Hybridoma Bank). Alexa Fluor 555 goat anti-rabbit
and anti-mouse (Molecular Probes) was used for secondary
staining. 4, 6-Diamidino-2-phenylindole (DAPI) was used
to counter-stain nuclei (Sigma).
Muscle preparation for mechanical studies
For the measurement of contractile properties, mice were
anesthetized with avertin (250 mg kg−1 intraperitoneal)
and analyzed as described previously [28, 30]. Intact TA
muscles were analyzed ex vivo in an experimental organ
bath filled with mammalian Ringer buffer, containing plat-
inum electrodes placed longitudinally on either side of the
muscle. Muscles were stimulated by electric field (square
wave pulses 25 V, 0.2 ms in duration, 150 Hz) using an op-
timal muscle length (L0) for the development of maximum
isometric tetanic force (F0). Specific force (sF0) was deter-
mined by normalizing maximum isometric tetanic force
(F0) to cross-sectional area (CSA). Total muscle CSA was
calculated by dividing muscle mass (mg) by the product of
muscle length (mm), and 1.06 mg/mm3 is the density of
mammalian skeletal muscle.
Results and discussion
Derivation and ex vivo expansion of satellite cells using
Pax3
To determine whether SCs maintained engraftment po-
tential when expanded ex vivo using conditional expres-
sion of Pax3, we followed the strategy summarized in
Fig. 1a, in which SCs from the transgenic Pax7-ZsGreen
reporter mouse [27] were (I) purified by flow cytometry,
(II) genetically modified with a lentiviral vector encoding
a doxycycline-inducible Pax3 transgene, (III) expanded
ex vivo in the presence of doxycycline, and then (IV)
transplanted into immune-deficient, dystrophin-deficient
NSG-mdx4Cv [31] mice. After enzymatic digestion, the
muscle mononuclear fraction of Pax7-ZsGreen was
FACS-purified based on ZsGreen expression, which re-
flects Pax7+ cells (Fig. 1b), and accordingly gave rise to a
homogeneous SC population (Fig. 1c). These cells were
immediately transduced with a doxycycline-regulated
conditional Pax3-IRES-mCherry-expressing lentivector
(Pax3 induced) [32]. As a control, SCs were transduced
with empty vector (mCherry only). Pax3+ (mCherry+)
cells were detected only when doxycycline (dox) was
added to the culture medium (Additional file 1). To
determine the effect of Pax3 on the expansion of trans-
duced SCs, we evaluated the proliferation rate of Pax3-
induced cells side-by-side with control cell prepara-
tions (empty vector) grown under identical culture
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conditions: proliferation medium with basic fibroblast
growth factor (bFGF) and dox. Notable expansion ad-
vantage was observed in Pax3-induced cultures when
compared to control counterparts (Fig. 1d). Although
under these proliferation conditions, both control and
Pax3-induced cells displayed similar morphology
(Fig. 1e, f, panel I), only Pax3-induced cells showed
abundant Pax3 expression, as evidenced by immuno-
fluorescence staining (Fig. 1e, f, panel II) and gene
expression analyses (Additional file 2). As expected,
Pax3 overexpression in SCs was accompanied by up-
regulation of its target gene Myf5 [35] (Additional file
2). Under proliferation conditions, Pax3-induced cells
showed no signs of myotube formation, as indicated by
the absence of signal for myosin heavy chain (MHC)
(Fig. 1f, panel III, and Additional file 2), whereas the
control uninduced population spontaneously differen-
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Fig. 1 Derivation and characterization of Pax3-induced satellite cells. a (I) FACS purification of satellite cells based on ZsGreen expression (Pax7),
(II) transduction of Pax7+ cells with an inducible expression system encoding Pax3, (III) in vitro expansion of Pax3-induced cells and control empty
vector counterparts, and (IV) transplantation of iPax3 and control cells into NSG-mdx4Cv. b Representative FACS profile for ZsGreen (Pax7) expression in
digested muscles isolated from Pax7-ZsGreen reporter mice. Sorting gate for ZsGreen+ (Pax7+) satellite cells is shown. c Phase-contrast image of sorted
ZsGreen+ (Pax7+) satellite cells. d Cell growth curve of Pax3-induced cells and control counterparts at several passages (P1–P4) (n = 2, mean ± SD).
e, f In vitro characterization of ex vivo expanded satellite cells grown under proliferation and differentiation culture conditions. Phase-contrast
images of control empty vector (e) and Pax3-induced (f) monolayers. Representative immunofluorescence staining for Pax3 (red, upper panels)
and MHC (red, lower panels) in control empty vector SCs (e) and Pax3-induced SCs (f). Cells are co-stained with DAPI (blue). Scale bar 200 μm.
g Fusion index calculation. Error bars represent s.e.m. (n = 3). **P < 0.01
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and Additional file 2). Nevertheless, when Pax3-
induced and control cells were subjected to differenti-
ation conditions (5 % horse serum and withdrawal of
dox and bFGF), both cultures gave rise to multinucle-
ated myotubes displaying abundant expression of
MHC (Fig. 1e, f, panels IV and V, and Additional file 2).
Control cultures expressed significant levels of MHC
under proliferation conditions, suggesting the propensity
of these cells to begin differentiation as soon as they have
reached confluence. We next quantified the fusion index
of control and Pax3-induced cultures. Upon in vitro differ-
entiation, Pax3-induced SCs exhibited elevated fusion
index (67 %) relative to control cultures (47 %). Thus,
under the conditions tested here, Pax3 induction allows
the in vitro expansion of less differentiated SCs, without
affecting their ability to terminally differentiate into fusing
myotubes.
In vivo regenerative potential of ex vivo expanded
satellite cells
To evaluate in vivo repopulation potential after 1 week of
ex vivo expansion, Pax3-induced and respective control
cell preparations were transplanted into the TA muscles of
NSG-mdx4Cv mice. Prior to cell transplantation, both hind
limbs were subjected to irradiation (12 Gy/leg) to deplete
endogenous SCs [31] and injury with cardiotoxin (CTX).
While the contra-lateral TA was injected with PBS,
350,000 Pax3-induced or control cells were injected into
the right TA. Five weeks after transplantation, TA muscles
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Fig. 2 Regenerative potential of Pax3-induced satellite cells following their transplantation into NSG-mdx4Cv mice. Engraftment analysis of control
empty vector (a, b) and Pax3-induced cells (iPax3) (c, d). Cross sections of TA muscles harvested from NSG-mdx4Cv mice that had been injected
with PBS (a, c) or satellite cells (b, d) were stained with antibody to dystrophin (red). Engrafted tissues from control and Pax3-induced cells are
represented by mice #03 and #05 and #07 and #09, respectively. DAPI is shown in blue. Scale bar, 50 μm. e Quantification of DYS+ myofibers in
treated muscles. Error bars represent s.e.m. (n = 6). *P < 0.03
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immunofluorescence staining for dystrophin. Whereas
DYS+ myofibers were virtually undetectable in PBS-
injected muscles (Fig. 2a, c), dystrophin expression was
observed in TA muscles that had been transplanted with
control (Fig. 2b) or Pax3-induced (Fig. 2d) cell prepara-
tions, with the latter showing higher engraftment levels
(Fig. 2e, 14 ± 7.4 vs. 37 ± 5.7 %, respectively).
Next, we determined whether myofiber engraftment
was accompanied by improvement in muscle strength.
As expected, the maximum isometric force for PBS-
injected TA muscles (contra-lateral legs) was low (Fig. 3a,
gray lines). In contrast, engrafted TA muscles showed
enhanced isometric force (Fig. 3a, red lines). Cell trans-
plantation of both control and Pax3-induced prepara-
tions resulted in improved absolute (Fig. 3b) and specific
(Fig. 3c) force of engrafted muscles when compared with
their respective PBS-injected contra-lateral muscles.
However, muscles that had been transplanted with Pax3-
induced cells displayed significantly superior functional
improvement (Fig. 3b, c) when compared to control cells
(1.52-fold). No statistical difference was observed in
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Fig. 3 Contractile properties of transplanted muscles and satellite cell homing. a Representative examples of maximum isometric tetanic force in
TA muscles that had been injected with PBS (contra-lateral leg, gray line) and control or Pax3-induced cells (red lines). Wild-type Bl6 mice were used for
reference control (dashed line). b, c Cell transplantation produces an improvement in absolute (F0, b) and specific (sF0 = F0 normalized to CSA, c) force.
Error bars represent s.e.m. from a total of six mice. *P < 0.05, **P < 0.01, ***P < 0.001. d In situ analysis reveals the presence of donor-derived satellite cells
(ZsGreen/Pax3-induced cells) in the host stem cell pool, as shown by the presence of cells co-stained for both Pax7 (red) and ZsGreen (green) (white
arrow) beneath the basal lamina (gray). e Upon reinjury, engrafted donor-derived satellite cells give rise to newly formed myofibers, as indicated by the
co-expression of DYS (red) and embryonic MHC (green) (white arrow). Arrowheads denote DYS−/eMHC+ host-derived new formed myofibers. DAPI is
shown in blue. Scale bar, 50 μm
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groups of mice. These results demonstrate that 7-day
cultured SCs expanded with Pax3 have a superior ability
to improve muscle function, compared to control empty
vector transduced counterparts.
To assess whether Pax3-induced cells have the capacity
to engraft the host SC compartment, and therefore
contribute to ongoing regeneration, engrafted TA muscles
were stained for ZsGreen and Pax7 to identify donor-
derived SC contribution. Histological analysis of trans-
verse sections of TA muscles 1 month after transplant-
ation clearly identified the presence of Pax7+ZsGreen+
cells beneath the basal lamina, suggesting that Pax3-
induced cells can engraft the SC pool (Fig. 3d). To
investigate whether donor-derived iPax3 SCs would
be able to contribute to ongoing muscle regeneration,
a cohort of mice transplanted with unlabelled Pax3-
induced cells were reinjured with CTX 1 month after
cell transplantation. Ten days after reinjury, we de-
tected donor-derived newly regenerated myofibers, as
indicated by the presence of DYS+/embryonic MHC+
myofibers (Fig. 3e, white arrows). Since we have used
half of the usual dose of CTX (5ul/5uM, instead of
10ul/10uM) for these reinjury studies, CTX injection
did not result in degeneration of the whole tissue,
and accordingly the presence of DYS+/eMHC− fibers
was detected. These results suggest that at least some
of engrafted Pax3-induced cells remain less differenti-
ated and are able to respond to a second round of
muscle injury.
Genetic repair of dystrophic Pax3-induced cells
We next applied genetic correction to ex vivo expanded
dystrophic SCs following the protocol outlined in Fig. 1a,
but using SCs harvested from mdx mice bred to carry
the Pax7-ZsGreen reporter (Fig. 4a). For genetic repair,
we used the human micro-dystrophinΔR4–23/ΔCT (μDYS)
transgene lacking the spectrin-like repeats 4–23 and the
C-terminus [36] and the non-viral Sleeping Beauty sys-
tem for transduction. First, we generated a Tn vector
(pKT2-Neo selection marker driven by the-Neo/hH2
μDYS; Fig. 4b) containing two divergent genes: a GFP/
Neo selection marker driven by the hEF1a-eIF4g pro-
moter and the human μDystrophin (μDYS) gene under
the control of a pHSA [37].
SCs were isolated by flow cytometry from Pax7-
ZsGreen/mdx mice (Fig. 4a), immediately transduced
with the doxycycline-inducible Pax3 vector, and grown
in doxycycline to induce Pax3 expression. It should be
noted that almost immediately upon placing the Pax7-
ZsGreen SCs into culture, the ZsGreen fluorescence is
lost. We now then transduced these non-fluorescent
cells with the μ-dystrophin correction vector, which
contained a GFP reporter, and sorted on this signal;
therefore, the culture was now constitutively green.
Dystrophin-deficient Pax3-induced cells were subse-
quently nucleofected with Tn vector and transposase
(engineered hyperactive variant SB100X [38]; Fig. 4b,
upper panel), using a plasmid ratio of 4:1, respectively,
which we have previously found to provide optimal in
Fig. 4 Correction of dystrophin-deficient Pax3-induced satellite cells using a human μDYS transgene. a FACS plot shows gate for the purification
of ZsGreen+ (Pax7+) satellite cells from Pax7-ZsGreen/mdx mice. b The Sleeping Beauty transposon system consists of transposon (Tn) and transposase
(SB100X) vectors. The Tn is a bicistronic promoter vector of 11.3 Kb containing the ubiquitin hEF1a-eIF4g (Pr, in gray) and the skeletal muscle-specific
skeletal α-actin promoter (pHSA, in black). The ubiquitin promoter drives a GFP-2A-Neo. This selection marker cassette is flanked by lox P sequences
(red). The human μDYS gene is under control of the pHSA. SB100X transposase proteins (red spheres) bind the DR sequences (yellow arrows)
within the two inverted repeats (IR/DR, arrowheads) and catalyze integration of the whole transposon transgene into the genome with high
efficiency. c Representative FACS profiles for enrichment steps used to isolate a pure and stable population of corrected GFP+ cells (μDYS-Pax3-induced
cells) following transfection with pKT2/μDYS and SB100X. Control consisted of dystrophin-deficient Pax3-induced cells (CTL) nucleofected with pKT2
transposon vector only (no transposase). d RT-PCR analysis for uncorrected (UNC, dystrophin-deficient Pax3-induced cells) and corrected
(Corr, μDYS-Pax3-induced cells) cells grown under proliferation (P) and differentiation (D) culture conditions shows the expression of human μDYS solely
in corrected cells. GAPDH was used as housekeeping gene
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vitro gene transfer for a large transgene [32]. Five days
after nucleofection, flow cytometry analysis revealed a
cell sub-population positive for GFP/μDYS (~1.2 %)
(Fig. 4b, lower panel). Following two rounds of sorting, a
highly enriched μDYS+ (GFP+) population was obtained
(>96 %) (Fig. 4b, lower panel). Expression of the trans-
gene in corrected cells was confirmed by RT-PCR analysis
using specific primers for the human μDYS transgene
(Fig. 4c). These results demonstrate the capacity for the
Sleeping Beauty system to deliver a large transgene
(11.3 Kb) into dystrophic activated SCs.
Regenerative potential of μDYS-Pax3-induced cells
To assess the regenerative potential of corrected μDys-
Pax3-induced cells in vivo, these cells were transplanted
into CTX-injured TA muscles of NSG-mdx4Cv mice. We
did not irradiate these mice as irradiation would be dis-
couraged in the clinical setting. One month following
transplantation, TA muscles were harvested and sections
were evaluated for engraftment by immunostaining
using a human DYSTROPHIN antibody that recognizes
the N-terminal epitope, which is preserved in the human
μDYS transgene. While no DYS expression was detected
in PBS-injected muscles (Fig. 5a), muscles that had been
transplanted with μDYS-Pax3-induced cells generated
large engrafted areas with DYS+ myofibers (Fig. 5b).
Quantification of engraftment revealed that approxi-
mately 20 % of fibers in transplanted muscles were μDY-
STROPHIN+, confirming the regeneration potential of
ex vivo corrected activated SCs.
We next investigated whether engraftment of corrected
μDYS-Pax3-induced cells was accompanied by functional
improvement. Engrafted muscles showed superior isomet-
ric (Fig. 6a), absolute (Fig. 6b), and specific (Fig. 6c) force
when compared to PBS-injected TA muscles.
To determine whether engrafted μDYS-corrected
Pax3-induced cells would have the same ability to re-
spond to injury as shown above for WT cells and would
therefore be capable of providing μDYSTROPHIN con-
tinuously, we reinjured muscles that had been previously
transplanted with μDYS-Pax3-induced cells. Ten days
following CTX injection, we stained muscle sections










PBS µDYS iPax3 cells
Fig. 5 Engraftment of μDYS-Pax3-induced cells into NSG-mdx4Cv mice. TA muscles harvested from NSG-mdx4Cv mice that had been injected with PBS
(a) or corrected ex vivo expanded satellite cells (μDYS-Pax3-induced cells) (b) were stained using an antibody specific for human DYSTROPHIN (red).
The DYS protein was detected only in the transplanted muscles. Two representative transplanted mice (b) are shown. DAPI is shown in blue. Scale bar,
50 μm. c Quantification of human μDYSTROPHIN+ myofibers in these transplanted muscles. Error bars represent s.e.m (n = 6)
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with embryonic MHC and human DYS antibodies. This
clearly showed the presence of donor-derived newly re-
generated muscle fibers that were double-positive for
μDYS and embryonic MHC (Fig. 6d, white arrows and
Additional file 3). Altogether, these results show that
transplantation of corrected μDYS-Pax3-induced cells
provides functional improvement of dystrophic muscles,
both in terms of muscle force generation and in terms of
their ability to respond to ongoing muscle injury and
stably express μDYS protein.
SCs isolated by flow cytometry have been demonstrated
to possess a tremendous capacity to improve muscle
function in mdx mice [31]; however, the impracticality
of isolating large numbers of SCs from living donors
as well as the requirement for gene correction, if consider-
ing an autologous transplantation setting, necessitates
ex vivo expansion. To date, only one study has reported a
combined cell/gene therapy approach using SCs in the
context of muscular dystrophy [18]. In this study, the au-
thors isolated SCs from a dystrophic mouse, transduced
them with a lentiviral vector encoding the mouse μDYS
transgene, and immediately transplanted them into the
dystrophic muscle and found that they were able to
differentiate into DYS+ fibers.
Several studies have investigated the transplantation of
cultures derived from prospectively isolated SCs. Blau
and colleagues demonstrated that culturing mouse SCs
on a substrate that mimics muscle tissue elasticity, and
in the presence of an inhibitor for p38MAPK, helped
maintain “stemness” features [10, 39]. Following a different
approach, Tapscott and colleagues expanded freshly
isolated canine SCs by activating the Notch signaling
pathway, which bestowed superior in vivo regenerative
ability upon SC-initiated cultures compared to controls
[20]. In a recent study, Rudnicki and colleagues reported
that short treatment of SCs with Wnt7a resulted in en-
hanced engraftment that was accompanied by improved
muscle function [40].
Herein, we demonstrate that upon conditional expres-
sion of Pax3, freshly isolated SCs can be successfully
expanded when compared to their cultured empty vector
control counterparts (Fig. 1d). Following their intramuscu-
lar transplantation into dystrophic mice, Pax3-induced
cells display greater regenerative potential than control
SCs, and engraftment levels correlated with a significant
improvement in muscle strength (Fig. 3a–c). Importantly,
we also show that engrafted Pax3-induced cells are cap-
able of seeding the SC pool and responding to a second
round of CTX-induced damage by generating newly
formed DYS+ fibers (Fig. 4d, e). In addition, we show that
Pax3-induced dystrophic SCs are amenable to genetic
correction. Using a non-viral Sleeping Beauty system car-
rying a human μDYS transgene, we corrected SCs from
dystrophin-deficient mice and found that these were
capable of differentiating into functional muscle fibers in









µDYS Embryonic MHC DAPIEmbryonic MHCµDYS
Fig. 6 Contractile function and response to reinjury by muscles engrafted with μDYS-Pax3-induced cells. a Representative examples of maximum
isometric tetanic force in TA muscles that had been injected with PBS (contra-lateral leg, gray line) or Pax3 induced (red line). b, c μDYS-Pax3-induced
cell transplantation produced a significant improvement in absolute (F0, b) and specific (sF0 = F0 normalized to CSA, c) forces. Error bars represent
s.e.m. from a total of six mice. **P < 0.01. d Immunofluorescence staining for embryonic MHC and μDYS in engrafted TA muscles analyzed 10 days
after CTX reinjury indicates the presence of newly formed donor myofibers as denoted by co-expression of human μDYS (red) and eMHC
(green) (arrows). Arrowheads show μDYS−/eMHC+ host-derived newly formed myofibers. Alexa-647 was used to detect eMHC. DAPI is
shown in blue. Scale bar, 50 μm
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dystrophic muscles (Fig. 6a–c), and producing new myofi-
bers upon CTX reinjury that remain positive for the μDYS
transgene.
Conclusions
We describe here a method for the ex vivo expansion of
SCs that facilitates genetic correction and importantly
allows for the retention of a population with the capacity
to regenerate muscle function. Unlike viral approaches
that target the myofiber, this approach provides a genetic
correction that is persistent and not transient as corrected
fibers are eventually lost due to normal muscle turnover.
If future studies demonstrate that this approach is simi-
larly efficient to expand human SCs, it may be useful to
provide human adult stem cell populations endowed with
muscle regeneration potential in vivo.
Additional files
Additional file 1: Generation of inducible-Pax3-Cells. Representative
FACS profile of Pax3 inducible cells grown under proliferation culture
conditions. Doxycycline was added to the proliferation medium at 0.75
μg/ml. mCherry+ cells are detected only in Pax3-induced cultures (plus
Dox).
Additional file 2: Real time PCR analyses of proliferating and
differentiating cultured satellite cells. Gene expressionanalysis of
control (grey bar) and Pax3 induced cells (black bar). Transcripts are
normalized to GAPDH. Error bars represent s.e.m. from replicates of three
independent experiments. (PDF 134 kb)
Additional file 3: Long-term engraftment of μDYS-Pax3-induced
cells into NSG-mdx4Cv mice and response to reinjury by muscles
engrafted with μDYS-Pax3-induced cells. (a) The DYS protein was
detected only in the transplanted muscles at 2 months after transplantation.
(b) Immunofluorescence staining for embryonic MHC (green) and μDYS
(red) in engrafted TA muscles (lower magnification). Alexa-647 was used to
detect eMHC. DAPI is shown in blue. Scale bar, 50 μm (PDF 2192 kb)
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